ReviewArchives of pharmacal research2021
Recent progress in development and applications of second near-infrared (NIR-II) nanoprobes.
Review in Archives of pharmacal research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- AT1R-mediated NIR-II/PA imaging-guided iCM exosome therapy for myocardial ischemia revascularization.Science advances · 2026Article
- Advanced biomaterials for targeting mature biofilms in periodontitis therapy.Bioactive materials · 2025Review
- 3D-Printable Photothermal and Temperature-Controlled Polycaprolactone Scaffolds Incorporating Gold Plasmonic Blackbodies for Bone Tissue Engineering.ACS applied materials & interfaces · 2025Article
- Nanoagent-Mediated Photothermal Therapy: From Delivery System Design to Synergistic Theranostic Applications.International journal of nanomedicine · 2025Review
- NIR-II fluorescence in lung cancer: advancing precision diagnosis and image-guided therapy.Frontiers in chemistry · 2025Review
- Progress of near-infrared-II fluorescence in precision diagnosis and treatment of colorectal cancer.Heliyon · 2023Review
- An injectable and thermosensitive hydrogel with nano-aided NIR-II phototherapeutic and chemical effects for periodontal antibacteria and bone regeneration.Journal of nanobiotechnology · 2023Article
- A biocompatible NIR-II light-responsive nanoknife for permanent male sterilization.Nanoscale advances · 2023Article
- Synthesis of Au-Ag bimetallic nanoparticles using Korean red ginseng (Panax ginseng Meyer) root extract for chemo-photothermal anticancer therapy.Archives of pharmacal research · 2023Article
- NIR-I Dye-Based Probe: A New Window for Bimodal Tumor Theranostics.Frontiers in chemistry · 2022Review
- NIR-II emissive AIEgen photosensitizers enable ultrasensitive imaging-guided surgery and phototherapy to fully inhibit orthotopic hepatic tumors.Journal of nanobiotechnology · 2021Article
- Near-Infrared-II Bioimaging forFrontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optical probes for near-infrared (NIR) light have clear advantages over UV/VIS-based optical probes, such as their low levels of interfering auto-fluorescence and high tissue penetration. The second NIR (NIR-II) window (1000-1350 nm) offers better light penetration, lower background signal, higher safety limit, and higher maximum permitted exposure than the first NIR (NIR-I) window (650-950 nm). Therefore, NIR-II laser-based photoacoustic (PA) and fluorescence (FL) imaging can offer higher sensitivity and penetration depth than was previously available, and deeper lesions can be treated in vivo by photothermal therapy (PTT) and photodynamic therapy (PDT) with an NIR-II laser than with an NIR-I laser. Advances in creation of novel nanomaterials have increased options for improving light-induced bioimaging and treatment. Nanotechnology can provide advantages such as good disease targeting ability and relatively long circulation times to supplement the advantages of optical technologies. In this review, we present recent progress in development and applications of NIR-II light-based nanoplatforms for FL, PA, image-guided surgery, PDT, and PTT. We also discuss recent advances in smart NIR-II nanoprobes that can respond to stimuli in the tumor microenvironment and inflamed sites. Finally, we consider the challenges involved in using NIR-II nanomedicine for effective diagnosis and treatment.
Indexed as
Identifiers
33538959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.